We are live on ! Find out more
RLAY icon

Relay Therapeutics
RLAY

172 hedge funds and large institutions have $1.1B invested in Relay Therapeutics in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 67 increasing their positions, 47 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

84% more call options, than puts

Call options by funds: $195K | Put options by funds: $106K

43% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 47

7% more funds holding

Funds holding: 161 → 172 (+11)

0.23% less ownership

Funds ownership: 107.05% → 106.82% (-0.23%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

33% less capital invested

Capital invested by funds: $1.64B → $1.1B (-$541M)

Holders
172
Holders Change
+11
Holders Change %
+6.83%
% of All Funds
2.73%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
23
Increased
67
Reduced
47
Closed
12
Calls
$195K
Puts
$106K
Net Calls
+$89K
Net Calls Change
-$316K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$14.8M
2
CC
Casdin Capital
New York
+$9.95M
3
BG
Bellevue Group
Switzerland
+$7.68M
4
O
OrbiMed
New York
+$5.4M
5
Two Sigma Investments
Two Sigma Investments
New York
+$4.31M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$24.8M
2
AG
Artal Group
Luxembourg
-$15.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.12M
4
BI
BVF Inc
California
-$8.12M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$6.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$8.06M -$6.62M -615,959 -39%
Goldman Sachs
27
Goldman Sachs
New York
$7.5M -$4.28M -397,846 -31%
FC
28
Finepoint Capital
Massachusetts
$7.32M +$1.82M +169,300 +24%
UBS AM
29
UBS AM
Illinois
$7.28M -$227K -21,087 -2%
Northern Trust
30
Northern Trust
Illinois
$6.74M +$76.7K +7,130 +0.9%
IHAM
31
Integral Health Asset Management
New York
$6.73M +$1.08M +100,000 +14%
Charles Schwab
32
Charles Schwab
California
$6.01M +$456K +42,411 +6%
RSCM
33
Rock Springs Capital Management
Maryland
$5.67M – – –
Morgan Stanley
34
Morgan Stanley
New York
$5.53M -$1.29M -119,926 -15%
DCM
35
Driehaus Capital Management
Illinois
$4.99M – – –
Bessemer Group
36
Bessemer Group
New Jersey
$4.92M – – –
O
37
OrbiMed
New York
$4.22M +$5.4M +501,966 New
TD Asset Management
38
TD Asset Management
Ontario, Canada
$4.18M +$2.52M +233,983 +89%
Two Sigma Investments
39
Two Sigma Investments
New York
$3.37M +$4.31M +400,673 New
Baillie Gifford & Co
40
Baillie Gifford & Co
United Kingdom
$3.32M -$181K -16,858 -4%
American Century Companies
41
American Century Companies
Missouri
$3.23M +$222K +20,653 +6%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$3.18M -$2.68M -249,268 -40%
JFG
43
Jefferies Financial Group
New York
$3.05M -$770K -71,600 -16%
Jacobs Levy Equity Management
44
Jacobs Levy Equity Management
New Jersey
$2.82M +$3.6M +335,071 New
Bank of New York Mellon
45
Bank of New York Mellon
New York
$2.71M +$8.16K +759 +0.2%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$2.57M +$3.13M +290,800 +2,019%
HP
47
Harbourvest Partners
Massachusetts
$2.49M – – –
HighTower Advisors
48
HighTower Advisors
Illinois
$2.4M +$3.07M +285,343 New
CSS
49
Cubist Systematic Strategies
Connecticut
$2.35M +$1.09M +101,612 +57%
TC
50
TwinBeech Capital
New York
$2.23M +$2.85M +265,344 New
1
2
3 4 5

RLAY Hedge Fund Activity: Q3 2023 in Review

172 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2023, worth a combined $1.1B — down 33% from $1.64B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new RLAY positions and 12 closed out — a net gain of 11 holders — while 67 added to existing stakes and 47 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $14.8M. The largest seller was State Street, cutting an estimated $24.8M.

  • 172 institutional investors held Relay Therapeutics (RLAY) as of Q3 2023, up from 161 in Q2 2023.
  • Funds reported $1.1B of Relay Therapeutics stock for Q3 2023, down 33% quarter-over-quarter.
  • 23 funds opened new Relay Therapeutics positions in Q3 2023 and 12 closed out, a net change of +11 holders.
  • The largest Relay Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $14.8M added.
  • The largest Relay Therapeutics seller in Q3 2023 was State Street, an estimated $24.8M sold.

Based on aggregated 13F filings for Q3 2023.